Connect with us

Health

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF – TCTMD

Prospective studies are needed and mechanisms unclear, but the findings raise hopes for off-target benefits, says J. Emanuel Finet.

Published

on

Article feature image

Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) / (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan, Senthil Selvaraj, MD (Hospital of the University of Pennsylvania,…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Fat biomolecules are associated with various cancers, show studies – News-Medical.Net
Article feature image
RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia – News-Medical.Net